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Introduction. Helicobacter pylori and Epstein–Barr virus (EBV) infection have recently been shown to be associated with gastric
diseases. Polymorphisms in genes encoding cytokines such as interleukin 10 (IL-10) and interleukin 1 Receptor (IL-1RN)
inﬂuence cytokine secretion levels and appear to contribute to the risk of developing gastroduodenal diseases. To our knowledge,
this is the ﬁrst preliminary study to address the association of coinfection withH. pylori and EBV and their correlation with genetic
predisposition in the development of gastric diseases.Methods. Gastric biopsy samples of 96 patients with diﬀerent gastric diseases
were used. Results. Our results showed that the rate of coinfection was higher in patients with gastric cancer than in patients with
normal gastric mucosa, active chronic gastritis, and MALT lymphoma. As regards the characterization of H. pilory strains, the
polymorphism s1m1i1 of vacA gene was more frequent in patients with MALT Lymphoma in comparison to others, while the
polymorphism s2m2i2 was most frequent in patients with normal gastric mucosa. In addition, patients who tested positive for the
cagA gene were more frequently those aﬀected with gastric cancer than those with inactive chronic gastritis. Similarly, the patients
with oipA gene ON were more frequently those with gastric cancer than those with inactive chronic gastritis. Conclusion.
According to our analysis, there was no correlation between coinfection and polymorphisms in genes encoding IL-10 and IL-1RN.
We conclude that various factors can be involved in the development of gastric diseases.
1. Introduction
Gastrointestinal diseases and gastric cancer (GC) are among
the most common pathologies worldwide [1]. In recent years,
Helicobacter pylori and EBV infection seem to be strongly
associated with the development of gastric diseases [2, 3].
H. pylori, a bacterium that colonizes the gastric mucosa
of more than 50% of the world’s population, is considered to
be a group 1 carcinogen by the International Agency for
Research on cancer [4].
Various virulence factors are involved in the develop-
ment of gastric diseases inH. pylori positive patients; among
these, the genes cagA, vacA, and oipA have an important role
[5]. &e cytotoxicity-associated gene A (cagA) is one of the
most signiﬁcant virulence factors ofH. pylori. It is associated
with the development of peptic ulcers and gastric cancer [6].
&e vacA gene encoding for VacA protein is capable of
inducing large host cell vacuoles in the cytoplasm of gastric
cells [7], while the oipA (outer inﬂammatory protein) gene
encodes one of the outer-membrane proteins that contribute
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to gastric inﬂammation, inducing IL-8 secretion by epithelial
cells [8].
OipA expression is predicted to be regulated by a slipped
strand mispairing system based on the number of CT di-
nucleotide repeats in the 5′ signal peptide coding region of
the gene, with “ON” meaning oipA is functional and “OFF”
nonfunctional. OipA functional status is involved in bac-
terial adherence to gastric epithelial cells and in mucosal
inﬂammation.
Treatment failure in H. pylori infections is the current
issue for physicians. &ere are many reasons for treatment
failure. &ese can be grouped into microorganism-related
factors, host-related factors, and treatment-related factors.
H. pylori resistance to antibiotics is widely recognized as the
chief reason for treatment failure.
H. pylori resistance to clarithromycin has been correlated
to point mutations in the peptidyl transferase region of
domain V of the 23S rRNA. &e most common mutation is
an A-to-G transition at position 2143 (A2143G) and at
position 2142 (A2143G).
EBV infection is present in more than 90% of the
population. Upon infection, the virus rests latent in
B lymphocytes throughout the person’s lifetime [9].
Moreover, the association of EBVwith gastric carcinoma
was reported for a case of lymphoepithelial-like gastric
carcinoma, but the mechanism used by the virus to de-
termine the oncogenesis is still unknown [10].
It seems that EBV deregulation of the expression of
immune response-related genes promotes marked intra or
peritumoral immune cell inﬁltration [11]. &e relationship
of H. pylori with early inﬂammatory precancerous lesions is
well known.
However, only a few studies have evaluated the partic-
ipation of EBV infection in these lesions.
Some studies have found evidence that EBV infects
epithelial cells of the atrophic gastric mucosa with a rela-
tively low frequency [12], whereas other studies favour
higher frequencies [13].
While both micro-organisms are responsible for the
most common infections worldwide, a small percentage of
infected patients will develop severe disease [14].
&e outcome of the infection depends on the relation-
ship between environment, host, and bacterial virulence
factors [15, 16]. Recently, the polymorphism of proin-
ﬂammatory cytokines such as IL1RN and anti-inﬂammatory
cytokines such as IL-10 has been implicated in clarifying
host factors in the development of gastric diseases [17].
In particular, IL1RN genotypes and low IL-10 pro-
duction have been associated with an increased risk for
severe gastric lesions in patients infected with both micro-
organisms [18].
In this preliminary study, we analyze H. pylori and EBV
coinfection and correlation with host genetic variability in
gastric tissues from adult patients with diﬀerent gastric
diseases in Italy.
In this study, we considered four groups of patients:
group with normal gastric mucosa (control group), group
with active chronic gastritis, group gastric MALT (Mucosa-
Associated Lymphoid Tissue) lymphoma, and group with
gastric cancer. &ese groups were deﬁned considering both
premalignant disease and most common malignant disease
correlated to micro-organisms such as MALT lymphoma
and gastric cancer. &e use of the groups was introduced to
individualize the impact of each disease singularly and
consequently to reduce possible statistical biases.
&e investigation was deemed to be of interest as Sicily
has one of the most complex mixed ethnic populations in
Europe due to its geographical position.
2. Materials and Methods
2.1. Patients and Sample Collection. &is study was per-
formed on a sample of 96 patients, 34.38% males, and
65.62% females, aged 20–87 years, mean 58.27 y.o. and
standard deviation (SD) 16.26 y.o.
2.2. We Considered Four Groups of 24 Consecutive Patients
(i) Group with normal gastric mucosa (Group NGM),
composed of 33.33% males and 66.67% females,
aged 22–71 years, mean 46.58 y.o. and standard
deviation (SD) 14.74 y.o
(ii) Group with active chronic gastritis (Group GCA)
composed of 37.50% males and 62.50% females,
aged 20–87 years, mean 49.04 y.o. and standard
deviation (SD) 16.83 y.o
(iii) Group with gastric cancer (Group KG), composed
of 33.33% males and 66.67% females, aged 55–
87 years, mean 69.88 y.o. and standard deviation
(SD) 8.68 y.o
(iv) Group with gastric MALT lymphoma (Group ML),
composed of 33.33% males and 66.67% females,
aged 57–80 years, mean 67.58 y.o. and standard
deviation (SD) 6.24 y.o
Exclusion criteria were as follows: previous attempts to
eradicate H. pylori and use of antibiotics or proton pump
inhibitor within 2weeks prior to endoscopy.
Each patient signed an informed consent form before
undergoing endoscopy.
2.3. Sample Collection and Histological Analysis. Gastric
biopsy samples were obtained from patients attending the
endoscopy ward of the Endoscopy Services of the A.O.U.P.
Paolo Giaccone (Palermo, Italy) and M. Raimondi Hospital,
San Cataldo (Caltanissetta, Italy). Two biopsy samples were
obtained from de the antrum and two from the gastric
corpus. One was used forH. pylori culture and the second for
histologic examination.
In patients suspected of having gastric cancer andMALT
lymphoma, samples were taken directly from the gastric
lesion.
One antrum sample and one corpus sample was ﬁxed in
formaline, paraﬃn-embedded, and stained with hematox-
ylin and eosin (HE). Inﬂammatory response was graded
according to the Sydney System by a single experienced
pathologist.
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2.4. DNA Isolation from Gastric Biopsies, H. pylori, and EBV
DNADetection by PCRMethodology. DNA from the biopsy
samples was extracted using a High Pure Template Prepa-
ration kit (Roche), in accordance with the manufacturer’s
instructions. &e extracted DNA was stored at − 20°C until
use.
H. pylori infection was diagnosed when the ureaseA gene
was detected with nested PCR, while the BAMHI-W frag-
ment region of the EBV genome was used as the target to
evaluate the presence of the virus, according to Di Carlo et al.
[19] and Giardina et al. [20].
2.5.Detectionof cagA, theEPIYAMotif, Typingof vacAAlleles,
andDeterminingoipAStatus. In order to detect the presence
of the cagA gene and to analyse the EPIYA motif, the DNA
from each strain was subjected to PCR, as described by
Panayotopoulou et al. [21]. In determining the EPIYAmotif,
three diﬀerent PCR products were obtained: EPIYA ABC
(550 bp), EPIYA ABCC (650 bp), and EPIYA ABCCC
(750 bp). &e signal peptide (s) and midregion (m) of the
vacA gene were ampliﬁed using the primers described by
Atherton et al. [22]. Four diﬀerent PCR products were
obtained: s1 (259 bp) and s2 (286 bp) from the s-region and
m1 (290 bp) and m2 (352 bp) from the m-region (Atherton
et al., 1995). Two diﬀerent PCR products were obtained from
the i-region: i1 (250 bp) and i2 (260 bp) [23]. OipA status
was determined in all strains by PCR and sequencing of the
signal region of the oipA gene, according to Yamaoka et al.
[24].
2.6. Determination of Point Mutations in the H. pylori 23S
rRNA Gene. In order to detect mutations related to clari-
thromycin resistance in the 23S rRNA gene and to establish
the number of CT repeats present in oipA, the same primers
used for the ampliﬁcation gene were employed.
&e resulting PCR products were subjected to gel
electrophoresis in a 2% agarose gel, subsequently puriﬁed
and concentrated for sequencing using Amicon Ultra 0.5ml
columns (Millipore). Puriﬁed amplicons were sequenced
directly with the same forward and reverse primers used in
the previous PCR, using an ABI PRISM BigDye Cycle Se-
quencing Ready Reaction kit (Applied Biosystems)
according to the instructions supplied by the manufacturer.
&e analysis of products was performed using BioEdit v.
7.2.0 software according to Chiarini et al. [25] and Fasciana
et al. [26].
2.7. Genotyping of Cytokine Polymorphisms. &e IL-1RN
exon 2 polymorphism was analyzed according to Rad et al.
[27] Conditions were as follows: 95°C for 5min, then 35
cycles of 95°C for 30 s, 50°C for 30 s, 72°C for 30 s, and ﬁnally
72°C for 5min. &e PCR products were analyzed by elec-
trophoresis on a 2% agarose gel stained with ethidium
bromide. Allele 1 (4 repeats) was 410 bp, allele 2 (2 repeats)
was 240 bp, allele 3 (5 repeats) was 500 bp, allele 4 (3 repeats)
was 325 bp, and allele 5 (6 repeats) was 595 bp in length,
according to Forte et al. [28]. Ampliﬁcation Refractory
Mutation System (ARMS-PCR) was used to type 819C/Tand
1082G/A IL-10 SNP, as described by Crivello et al. [30].
3. Statistical Analysis
Data are presented as number and percentage for categorical
variables, and continuous data are expressed as mean-± standard deviation (SD), unless otherwise speciﬁed. &e
multiple comparison chi-square test was used to deﬁne
signiﬁcant diﬀerences among percentages: if chi-square test
was positive (p value <0.05), then residual analysis with the
Z-test to locate the highest or lowest signiﬁcant presence was
performed. To evaluate signiﬁcant diﬀerences of means
among groups, we performed the multicomparison ANOVA
test. When the ANOVA test was positive (p value <0.05),
pairwise comparisons were performed with Scheﬀe´’s test.
Univariate and multivariate linear correlation analysis
was performed, where the test on Pearson’s linear correla-
tion coeﬃcient R was performed with t-Student test, under
null hypothesis of Pearson’s linear correlation coeﬃcient
R� 0. In this step for dichotomies, we deﬁned the experi-
mental probability distribution for the variables Gender, Hp,
EBV, and Coinfected, assigning them the following values:
(i) For Gender, male� 1 and female� 0
(ii) Hp, presence� 1 and absence� 0
(iii) EBV virus, presence� 1 and absence� 0
(iv) Coinfected (patients with HP and EBV virus),
yes� 1, and no� 0
For polymorphism variables vacA, IL-1RN, and IL-10,
we deﬁned, according to the frequency of the variable’s
modalities in our total sample data, the following scales,
respectively:
(i) s2m2i2� 5, s1m1i1� 4, s1m2i1� 3, s1m2i2� 2, and
s1m1-m2i1� 1 and polymorphism absence� 0
(ii) 1/1� 5, 1/2� 4, 2/2� 3, 1/3� 2, and 4/4�1 and
polymorphism absence� 0
(iii) AA� 3, AG� 2, and GG� 1 and polymorphism
absence� 0
For the gastric disease variables, we used the following
scale:
(i) NGM� 1, GCA� 2, ML� 3, and KG� 4.
We considered all statistical tests with p value <0.05 to be
signiﬁcant. All data were analyzed with Matlab statistical
toolbox version 2008 (MathWorks, Natick, MA, USA) for
32 bit Windows.
4. Results and Discussions
In this preliminary study, we evaluated the relationship
between H. pylori and EBV infection, and cytokine poly-
morphism in gastric diseases in people living in the Med-
iterranean area [26, 30]. In our study, the positivity rate ofH.
pylori in patients with gastric cancer was higher than that
found in patients with normal gastric mucosa, active chronic
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gastritis, and MALT lymphoma, namely, 50%, 45.83%,
41.67%, and 45.83%, respectively.
EBV was detected in 54.17% of the patients with gastric
cancer. It was detected in smaller percentages in patients
with normal gastric mucosa, active chronic gastritis, and
MALT lymphoma, namely, 20.83%, 41.67%, and 37.50%,
respectively. In any case, the rate of H. pylori in all patients
analyzed was 45.83%, and the rate of EBV was 38.54%.
&e rate of coinfection was higher in patients with gastric
cancer than that in patients with normal gastric mucosa,
active chronic gastritis, and MALT lymphoma, namely,
37.50%, 16.67%, 29.17%, and 25%, respectively. &e cagA
and vacA genes are commonly used as markers to charac-
terize H. pylori virulence. Several epidemiological studies
have reported geographical variations in the circulation of
the virulence factors pertaining to the micro-organisms. In
Sicily, the cagA gene is present in 52.27% of strains: in 97% of
the strains, it is associated with the ABC EPIYAmotif, and in
most, it is associated with the presence of the s1i1m1 vacA
allele.
In this study, the rate of H. pylori resistance to clari-
thromycin was high, occurring in 27% of the cases. &emost
frequent point mutation in the peptidyl transferase loop
region of the 23S rRNA gene was A2143G in 83% of resistant
strains. &ese data conﬁrm those reported by Fasciana et al.
in a previous study [26].
Table 1 shows clinical information of the total patient
sample, including age, gender, symptoms, and infection
type, patients infected by H. pylori, by EBV or both
(coinfected). In addition, we identify four groups according
to symptom type: normal gastric mucosa (NGM), active
chronic gastritis (GCA), gastric cancer (KG), and MALT
lymphoma (ML).
In Table 2, we have summarized the results of our gene
analysis. &e table shows the percentages of polymorphism
of vacA gene, polymorphism IL-1RN, and polymorphism
IL-10 (− 1082). In addition, in patients where the gene vacA
was present, the percentage of those with gene cagA positive
and oipA “ON” status is reported.
In Table 3, we have described in detail the four groups
according to symptom type, reported in Table 1. For each
group, we have reported age, gender, infection type (in-
cluding patients infected by H. pilory, EBV, or both), and
polymorphism vacA type. In patients where vacA was
present, the percentage of those with gene cagA positive and
oipA “ON” is indicated. Finally, in the last column, we report
the results of univariate and multivariate analysis among
groups.
In Table 3, we can observe a signiﬁcant diﬀerence for age
(p value <0.001); in particular, there was a signiﬁcantly higher
number of elderly patients in the gastric cancer and MALT
lymphoma groups, in accordance with Ferlay et al. [1].
As regards the characterization of H. pilory strains,
evaluated directly on gastric biopsies, the polymorphism
s1m1i1 of vacA gene was more frequent in Group ML (p
value� 0.0169), while the polymorphism s2m2i2 was most
frequent in Group NGM (p value� 0.0359) and less frequent
in Group KG (p value� 0.0276). In other words, the
polymorphism s1m1i1 was signiﬁcantly associated with
patients with MALT lymphoma, while the polymorphism
s2m2i2 was signiﬁcantly associated with patients with in-
active chronic gastritis.
In addition, the patients positive for cagA gene were more
frequently those aﬀected by gastric cancer (p value� 0.0198)
and less frequently those with inactive chronic gastritis
compared to patients with other diseases (p value� 0.0130). A
similar situation was found for the oipA gene. Patients with
oipA gene and “ON” status were more frequently those with
Table 1: Clinical information: age, gender, symptoms, and in-
fection type in the total patient sample.
Parameters Sample data
Age 58.27± 16.26
Gender
Male 34.38% (33/96)
Female 65.62% (63/96)
Symptoms
NGM 25.00% (24/96)
GCA 25.00% (24/96)
ML 25.00% (24/96)
KG 25.00% (24/96)
Analysis with PCR
Not infected 42.71% (41/96)
Infected by HP 45.83% (44/96)
Infected by EBV 38.54% (37/96)
Coinfected 27.08% (26/96)
NGM�normal gastric mucosa; GCA� active chronic gastritis; KG� gastric
cancer; ML�MALT lymphoma; HP�H. pylori; coinfected� patients with
HP and EBV.
Table 2: Gene analysis of our sample data.
Parameters Sample data
Polymorphism of gene vacA
s1m1-m2i1 2.27% (1/44)
s1m2i2 4.55% (2/44)
s1m2i1 6.82% (3/44)
s1m1i1 40.91% (18/44)
s2m2i2 45.45% (20/44)
Gene cagA (†)
Negative 47.73% (21/44)
Positive 52.27% (23/44)
Gene oipA (†)
“OFF” 47.73% (21/44)
“ON” 52.27% (23/44)
Polymorphism IL-1RN
1/1 56.35% (54/96)
1/2 21.88% (21/96)
2/2 18.75 (18/96)
1/3 2.08% (2/96)
4/4 1.04% (1/96)
Polymorphism IL-10 (− 1082)
AA 47.92% (46/96)
AG 29.17% (28/96)
GG 22.92% (22/96)
H. pylori resistant 27.27% (12/44)
H. pylori sensible 72.73% (32/44)
HP�H. pylori; GCNA� inactive chronic gastritis; GCA� active chronic
gastritis; KG� gastric cancer; ML�MALT lymphoma; †cases where gene
vacA was present.
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gastric cancer (p value� 0.0198) and less frequently those with
inactive chronic gastritis (p value� 0.0130).
Regarding number of CT repeats, the most prevalent in
the “ON” frame status had six CTrepeats. &is was found to
be the case in other studies [26, 30]. Among the out-frame
status, “OFF” variants, the patterns with eight CT repeats
were the most prevalent.
&e evidence pointing to the oipA “ON” as a gastric
cancer risk factor includes the ability of the bacterium
carrying a functional oipA to attach to the gastric epi-
thelial cells and induce inﬂammation, apoptosis, and a
toxic eﬀect on towards cultured gastric epithelial cell
lines.
In Table 4, we can see the sequences of signal peptide-
encoding region of oipA.
Analysis of the 23S rRNA gene demonstrated that 32
(73%) patients were infected with H. pylori-susceptible
strains and the remaining 12 (27%) with resistant strains
(Table 2). &e predominant point mutation observed among
the 12 H. pylori resistant strains was A2143G in 10 cases (83
%) and A2142G in 2 cases (17%).
In Table 5, we report the frequency of polymorphism
IL1RN and IL-10 loci for every group. In the last column, we
report the results of univariate and multivariate analysis
performed among the groups.
Table 5 shows that there was only one signiﬁcant as-
sociation between polymorphism IL-1RN and gastric dis-
ease. Particularly, patients with polymorphism IL-1RN type
1/2 were signiﬁcantly less frequent in the ML Group (p
value� 0.0248).
Table 3: Characteristics of the groups: normal gastric mucosa (NGM), active chronic gastritis (GCA), gastric cancer (KG), and MALT
lymphoma (ML). Results of univariate and multivariate analysis among groups.
Parameters Group NGM Group GCA Group KG Group ML Univariate and multivariate analysis
Age 46.58± 14.74 49.04± 16.83 69.88± 8.68 67.58± 6.24
p< 0.001 (A)
NGM<KG, p< 0.05∗ (Sh)
NGM<ML, p< 0.05∗ (Sh)
GCA<KG, p< 0.05∗ (Sh)
GCA<ML, p< 0.05∗ (Sh)
NGM<GCA, p> 0.05 (Sh)
ML<KG, p> 0.05 (Sh)
Gender
Male 33.33% (8/24) 37.50% (9/24) 33.33% (8/24) 33.33% (8/24) p � 0.987 (C)
Female 66.67% (16/24) 62.50% (15/24) 66.67% (16/24) 66.67% (16/24) p � 0.987 (C)
Analysis with PCR
Not infected 50.00% (12/24) 45.83% (11/24) 33.33% (8/24) 41.67% (10/24) p � 0.987 (C)
Infected by HP 45.83% (11/24) 41.67% (10/24) 50.00% (12/24) 45.83% (11/24) p � 0.953 (C)
Infected by EBV 20.83% (5/24) 41.67% (10/24) 54.17% (13/24) 37.50% (9/24) p � 0.124 (C)
Coinfected 16.67% (4/24) 29.17% (7/24) 37.50% (9/24) 25.00% (6/24) p � 0.433 (C)
Polymorphism vacA
s1m1i1 9.09% (1/11) 10.00% (1/10) 58.33% (7/12) 81.82% (9/11) p< 0.0001 (C)∗ML, p � 0.0169 (Z)∗∗
s1m2i1 0.00% (0/11) 10.00% (1/10) 16.67% (2/12) 0.00% (0/11) p � 0.308 (C)
s1m2i2 9.09% (1/11) 0.00% (0/10) 8.33% (1/12) 0.00% (0/11) p � 0.589 (C)
s2m2i2 81.82% (9/11) 80.00% (8/10) 8.33% (1/12) 18.18% (2/11)
p< 0.0001 (C)∗
NGM, p � 0.0359 (Z)∗∗
KG, p � 0.0276 (Z)∗∗∗
s1m1-m2i1 0.00% (0/11) 0.00% (0/10) 8.33% (1/12) 0.00% (0/11) p � 0.435 (C)
Gene cagA (†)
Negative 90.91% (10/11) 80.00% (8/10) 8.33% (1/12) 18.18% (2/11)
p< 0.0001 (C)∗
NGM, p � 0.0130 (Z)∗∗
KG, p � 0.0198 (Z)∗∗∗
Positive 9.09% (1/11) 20.00% (2/10) 91.67% (11/12) 81.82% (9/11)
p< 0.0001 (C)∗
KG, p � 0.0198 (Z)∗∗
NGM, p � 0.0130 (Z)∗∗∗
Gene oipA (†)
“OFF” 90.91% (10/11) 80.00% (8/10) 8.33% (1/12) 18.18% (2/11)
p< 0.0001 (C)∗
NGM, p � 0.0130 (Z)∗∗
KG, p � 0.0198 (Z)∗∗∗
“ON” 9.09% (1/11) 20.00% (2/10) 91.67% (11/12) 81.82% (9/11)
p< 0.0001 (C)∗
KG, p � 0.0198 (Z)∗∗
NGM, p � 0.0130 (Z)∗∗∗∗signiﬁcant test; ∗∗signiﬁcant most frequent; ∗∗∗signiﬁcant less frequent; A�multicomparison ANOVA test; Sh� post hoc Scheﬀe´’s test for pairwise
comparison; C�multicomparison chi-square test; Z�Z-test; HP�H. pylori; coinfected� patients with HP and EBV; NGM� normal gastric mucosa;
GCA� active chronic gastritis; KG� gastric cancer; ML�MALT lymphoma; † � cases where gene vacA was present; p � p value.
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Table 4: oipA CT repeat patterns.
Sequence of signal peptide-encoding region of oipA No. CT No. of strains
OFF status
ATGAAAAAAGCTCTCTTA. . .. . .. . .CTCTCTCTCTCTCTCTCTCGTT 9 5
ATGAAAAAAGCCCTCTTACTAACTCTCTCTCTCTCTCTCGTTT 8 7
ATGAAAAAAGCTCTCTTGCTAACTCTCTCTCTCTCTCTCTCTCGTT 10 2
ATGAAAAAAGCTCTTTTA. . .. . .. . .CTCTCTCTCTCTCGTT 6 3
ATGAAAAAAGCTCTCTTACTAACTCTCTCTCTCTCTCGTT 7 2
ATGAAAAAGCTCTCTTA. . .. . .. . .CTCTCTCTCTCTCTCGTTCTGG 7 1
ATGAAAAAAGCCCTCTTA. . .. . .. . .CTCTCTCTTTCTCTCGTTTT 4+ 2 1
Total 21
ON status
ATGAAAAAAGCTCTCTTACTAATTCTCTCTCTCTCGTT 5 4
ATGAAAAAAGCTCTCTTACTAACTCTCTCTCTCTCGTT 6 15
ATGAAAAAAGCCCTCTTA. . .. . .. . .CTCTCTCTCTCTCTCTCTCTCTCGT 11 2
ATGAAAAAAGCTCTCTTACTAACT CTCTCTCTCTCTCTCTCGTT 9 1
ATGAAAAAAGCTCTTTTACTCTCT CTCTCTCTCTCGTT 8 1
Total 23
Table 5: Frequency of the polymorphisms IL1RN and IL-10 loci. Results of univariate and multivariate analysis among groups.
Parameters Group NGM Group GCA Group KG Group ML Univariate and multivariate analysis
Polymorphism IL-1RN
1/1 50.00% (12/24) 62.50% (15/24) 41.67% (10/24) 70.83% (17/24) 0.179 (C)
1/2 29.17% (7/24) 25.00% (6/24) 33.33% (8/24) 0.00% (0/24) 0.0239 (C)
∗
group ML∗∗∗, p � 0.0248 (Z)
2/2 20.83% (5/24) 8.33% (2/24) 16.67% (4/24) 29.17% (7/24) 0.314 (C)
1/3 0.00% (0/24) 4.17% (1/24) 4.17% (1/24) 0.00% (0/24) 0.564 (C)
4/4 0.00% (0/24) 0.00% (0/24) 4.17% (1/24) 0.00% (0/24) 0.387 (C)
Polymorphism IL-10 (− 1082)
AA 41.67% (10/24) 45.83% (11/24) 54.17% (13/24) 50.00% (12/24) 0.841 (C)
AG 33.33% (8/24) 33.33% (8/24) 29.17% (7/24) 20.83% (5/24) 0.875 (C)
GG 25.00% (6/24) 20.83% (5/24) 16.67% (4/24) 29.17% (7/24) 0.768 (C)∗Signiﬁcant test; ∗∗signiﬁcant most frequent; ∗∗∗signiﬁcant less frequent; #� no localized signiﬁcant modality with signiﬁcant level <0.05;
C�multicomparison chi-square test; Z�Z-test; HP�H. pylori; NGM�normal gastric mucosa; GCA� active chronic gastritis; KG� gastric cancer;
ML�MALT lymphoma; p � p value.
Table 6: Results of univariate and multivariate linear correlation analysis between polymorphism of vacA, IL-1RN and IL-10 with age,
gender, H. pylori, EBV, coinfected, and gastric disease.
Linear correlation analysis Univariate analysis Multivariate analysis
R (p value) Multiple linear correlation coeﬃcient� 0.149
Polymorphism IL-1RN/age − 0.092 (0.371) Rpartial � − 0.057; p value� 0.593
Polymorphism IL-1RN/gender − 0.038 (0.716) Rpartial � − 0.013; p value� 0.905
Polymorphism IL-1RN/H. pylori 0.02 (0.846) Rpartial � − 0.027; p value� 0.800
Polymorphism IL-1RN/EBV − 0.027 (0.794) Rpartial � 0.052; p value� 0.622
Polymorphism IL-1RN/coinfected − 0.015 (0.886) Rpartial � − 0.011; p value� 0.917
Polymorphism IL-1RN/gastric disease − 0.097 (0.348) Rpartial � − 0.107; p value� 0.314
R (p value) Multiple linear correlation coeﬃcient� 0.215
Polymorphism IL-10/age 0.116 (0.259) Rpartial � 0.106; p value� 0.316
Polymorphism IL-10/gender − 0.142 (0.167) Rpartial � − 0.125; p value� 0.237
Polymorphism IL-10/H. pylori 0.102 (0.322) Rpartial � − 0.024; p value� 0.821
Polymorphism IL-10/EBV 0.081 (0.430) Rpartial � − 0.054; p value� 0.619
Polymorphism IL-10/coinfected 0.101 (0.329) Rpartial � 0.062; p value� 0.560
Polymorphism IL-10/gastric disease 0.061 (0.552) Rpartial � 0.027; p value� 0.797∗Signiﬁcant test; R�Pearson’s linear correlation coeﬃcient; Rpartial � the partial correlation coeﬃcient is the coeﬃcient of correlation of the variable with the
dependent variable, adjusted for the eﬀect of the other variables in the mode; coinfected� patients with H. pylori and EBV.
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&ese results, in accordance with other reports, do not
seem to attribute any particular role to proinﬂammatory or
anti-inﬂammatory cytokine genotypes in gastric disease
susceptibility [28].
Finally, in Table 6, we report the results of univariate and
multivariate linear correlation analyses between poly-
morphisms IL-1RN and IL-10, with the independent variables
age, gender, H. pylori infection, EBV infection, coinfection,
and gastric disease. In this case, no correlations were found.
5. Conclusions
We can conclude that the various factors that can be in-
volved in cancer development are very complex. A limitation
of this study was the limited number of patients with the
various gastric diseases. &erefore, further investigations are
necessary to fully correlate the role of coinfection in gastric
diseases in the Sicilian population. In addition, coinfection
should be evaluated at an early age and in children with an
increased risk of presenting more serious lesions later in life.
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